Lyell ImmunopharmaLYEL
13F holders, Q2 2025 (June 30)6holders −106
1new positions
51sold out
$8.84avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Lyell Immunopharma Inc. (LYEL) in their 13F filings, down 106 from Q1 2025. 1 opened new positions and 51 sold out. The largest holders were MWG Management Ltd. ($8.9M), Orland Properties Ltd ($6.7M) and Decheng Capital LLC ($5.3M).
- Company
- Lyell Immunopharma Inc.
- CUSIP
- 55083R104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $28 |
| Exits | 51 | $2.6M |
All 13F filers, Q1 2025 → Q2 2025: 63 shares bought and 241,841 shares sold, net −241,778 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| MWG Management Ltd. | 17.17% | No change | 1,008,116 | $8.9M |
| Orland Properties Ltd | 2.83% | No change | 754,698 | $6.7M |
| Decheng Capital LLC | 1.33% | No change | 595,466 | $5.3M |
| Johnson & Johnson | 0.11% | No change | 41,165 | $368K |
| Takeda Pharmaceutical Co. Ltd. | 1.86% | No change | 41,165 | $364K |
| IFP Advisors, Inc | 0.00% | New | 63 | $28 |
"% of holder's portfolio" is LYEL's weight in each manager's 13F, not the share of Lyell Immunopharma Inc. the manager owns.